Pharming Group today announced it has received European Medicines Agency (EMA) approval of a Type II Variation for a new production facility for its lead product, RUCONEST®.
Pharming announces today the placement of €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The offer was fully subscribed. The Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, South Africa and Japan.
Highlights • Replaces and repays the loan facility with Orbimed • Accelerates expansion of production and commercial capability, including the new territories reacquired from Sobi • Allows Pharming to extend its debt maturity profile through the period of development of its existing pipeline
Pharming Group N.V. (Euronext Amsterdam: PHARM) today announced it has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, RUCONEST®, in all remaining territories, which includes all remaining EU markets. Under the agreement, the license is being terminated with effect from 1 January 2020 in all 36 countries with a smooth handover planned in the countries where Sobi has sales activities. Pharming will pay Sobi €7.5 million in two tranches.
Pharming presents at the first "PharmingForum" Day on the 26th of October 2019 in Gilze en Rijen. Pharming was honoured to present to the forum members alongside our esteemed colleague Professor Michael Osthoff, M.D. from Basel University.
CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao.
Pharming categorically denies having had any involvement in the alleged abstraction of proprietary information by Dr Joseph Chiao from his former employer CSL
CEO of Pharming Sijmen de Vries presented at the 21st Annual Global Life Science Investment Conference on the 9th of September in New York City.
